Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMIT: Low vs Medium Intensity CKRT in Critically Ill Patients
NCT06014801Phase 3Recruiting
- Sponsor
- Jikei University School of Medicine
- Start
- Oct 2023
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute kidney injury (AKI) (2 arms), sponsored by Jikei University School of Medicine. Primary endpoint: Composite of death and duration of kidney replacement therapy at 28 days. Started Oct 2023; status: recruiting.
02
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06014801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014801.